Literature DB >> 17195067

WP760, a melanoma selective drug.

Mingzhong Zheng1, Waldemar Priebe, Eugene T Walch, Katherine G Roth, Mikyung Han, Chi-Hui Tang, Sangkyou Lee, Nancy J Poindexter, Izabela Fokt, Elizabeth A Grimm.   

Abstract

PURPOSE: Our goal was to perform studies on the specificity and antimelanoma mechanism of a novel bis-anthracycline, WP760. WP760 initially identified in the NCI 160 screen as anti-melanoma.
METHODS: The methyl thiazolyl tetrazolium reduction (MTT) assay was used to test tumor cell growth inhibition; confocal microscopy to view WP760 intracellular distribution; flow cytometry for cell-cycle arrest and apoptosis; and Western blotting was employed to identify and compare quantities and kinetics of cell growth related molecule levels.
RESULTS: WP760 induced G(2)/M-phase cell-cycle arrest and apoptosis in melanoma cell lines and short-term melanoma explants established from clinical specimens in a time and concentration dependent manner at nM concentrations. In contrast, effects on fibroblasts and A549 lung cancer cells required higher concentrations, suggesting that WP760 possesses selectivity for melanoma. Molecular studies indicated that WP760 induced p53 stabilization, checkpoint kinase 2 and p27(Kip1) protein upregulation, and activation of caspase-3. Endogenous nitric oxide (NO) production has been implicated in the chemoresistance of melanoma; WP760 caused inhibition of the inducible nitric oxide synthase (iNOS) protein as well as inhibition of phosphorylation of ERK, known to drive the iNOS pathway. Based on WP760 localization into mitochondria, and caspase-3 inhibitor block the killing of WP760, the intrinsic pathway of apoptosis appears to have been activated.
CONCLUSIONS: Our results indicate that WP760 affects a critical and unique set of growth regulatory effects in melanoma, and is a promising candidate for further preclinical studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195067     DOI: 10.1007/s00280-006-0404-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

Review 1.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target.

Authors:  Elizabeth A Grimm; Andrew G Sikora; Suhendan Ekmekcioglu
Journal:  Clin Cancer Res       Date:  2013-07-18       Impact factor: 12.531

2.  Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin.

Authors:  Luiz C Godoy; Chase T M Anderson; Rajdeep Chowdhury; Laura J Trudel; Gerald N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

3.  Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.

Authors:  Magdalena Olbryt; Aleksandra Rusin; Izabela Fokt; Anna Habryka; Patrycja Tudrej; Sebastian Student; Aleksander Sochanik; Rafał Zieliński; Waldemar Priebe
Journal:  Invest New Drugs       Date:  2017-04-17       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.